The FDA has accepted Stealth BioTherapeutics’ third new drug application for its ultra rare disease candidate, providing a ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

The developer of an alternative surgical approach to glaucoma has raised $42 million to bolster the commercial launch of its ...

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

The years-long legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight ...

Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...